Considering that the major phenotype of global CD36 knockout mice and humans born with CD36 deficiency is hypertriglyceridemia [103,104], we are curious whether similar effects will also be seen in humans treated with anti-CD36 therapy. The gene discussed is CD36; the disease is hypertriglyceridemia.